Personal Finance

Archived Event: Dr. Dale Schenk, CEO of Prothena Corporation plc [PRTA]

Watch the archived CEO Signature Series interview with Dr. Dale Schenk, the CEO of Prothena Corporation plc [PRTA] (The interview was recorded on: Wednesday, February 13, 2013)

Dr. Dale Schenk, Chief Executive Officer of Prothena, was most recently Chief Scientific Officer and Executive Vice President at Elan Pharmaceuticals where he provided the leadership and scientific direction for Elan's research and development programs.

Prior to joining Elan, Dr. Schenk was a founding scientist of Athena Neurosciences which was acquired by Elan Pharmaceuticals. Dr. Schenk has pioneered the immunotherapeutic approach for the treatment of amyloidosis, as exemplified for Alzheimer's disease.

Dr. Schenk's work in this area - as well as in early detection, testing and other pathways to the disease - has led to the most advanced potential treatment approaches for Alzheimer's disease. Dr. Schenk earned his BA and PhD in Pharmacology and Physiology from the University of California, San Diego.

Visit the Summary Quote page for the latest stock price for PRTA. You can find the latest company press releases in the news area of NASDAQ.com.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PRTA

Other Topics

Banking